Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?

Increasing evidence is being reported regarding the hypothesis that several proinflammatory and anti-inflammatory cytokines may promote tumor progression and affect the host antitumor response. However, the manner in which a local cytokine network operates in tumor development remains unclear. We reviewed the literature to examine the consequences of novel insights into inflammatory cytokines associated with gastric cancer progression. The Medline and EMBASE databases were searched for publications regarding the role of inflammatory cytokines in the development of gastric cancer. A number of studies have suggested that several proinflammatory and anti-inflammatory cytokines promote tumor progression through the direct activation of nuclear factor-κB (NF-κB) and the upregulation of angiogenesis and adhesion molecules. Furthermore, these processes suppress host antitumor immunity, leading to tumor progression and metastasis. In patients with advanced gastric cancer, most cytokines that enhance or suppress host antitumor immunity appear to have elevated serum and local expression levels. The net cytokine environment fluctuates at various stages of tumor development. In conclusion, a more detailed understanding of the differential roles of malignant cell-derived and hostderived cytokines at different stages of the malignant process could, consequently, open new avenues for the manipulation of cytokine expression and function in cancer immunotherapy for gastric cancer.

[1]  Y. Hsieh,et al.  Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood. , 2001, Annals of clinical and laboratory science.

[2]  S. Tsujitani,et al.  The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. , 1999, Cancer.

[3]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[4]  W. Gong,et al.  Chemokines and their role in tumor growth and metastasis. , 1998, Journal of immunological methods.

[5]  L. Hou,et al.  Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. , 2007, Carcinogenesis.

[6]  I. Fidler,et al.  Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice , 1999, British Journal of Cancer.

[7]  K. Yanagihara,et al.  Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. , 1992, Cancer research.

[8]  T. Ichikura,et al.  Significant correlation between expression of interleukin‐1α and liver metastasis in gastric carcinoma , 2001, Cancer.

[9]  H. Aburatani,et al.  Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β Signaling , 2009 .

[10]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[11]  S. Murakami,et al.  Serum Interleukin-12 Levels in Patients with Gastric Cancer , 2004, Surgery Today.

[12]  I. Fidler,et al.  Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  W. Paul Pleiotropy and redundancy: T cell-derived lymphokines in the immune response , 1989, Cell.

[14]  P. Malfertheiner,et al.  The Association Between the Interleukin-1 Polymorphisms and Gastric Cancer Risk Depends on the Family History of Gastric Carcinoma in the Study Population , 2006, The American Journal of Gastroenterology.

[15]  F. Balkwill Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[16]  Albert Zlotnik Chemokines and cancer , 2006, International journal of cancer.

[17]  T. Ichikura,et al.  Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: a possible role in tumor progression. , 2005, Anticancer research.

[18]  M. Pistelli,et al.  Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. , 2009, Cancer treatment reviews.

[19]  Tetsuo Sumi,et al.  Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor , 2005, Gastric Cancer.

[20]  I. Fidler,et al.  Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. , 1998, The American journal of pathology.

[21]  S. Wahl,et al.  TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression , 2003 .

[22]  T. Sasada,et al.  CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies , 2003, Cancer.

[23]  S. Kamiya,et al.  Analysis of interleukin‐8 secretion induced by Helicobacter pylori from the gastric epithelial cell line MKN45: A mechanism independent of the intensity of cytotoxicity , 1997, Journal of gastroenterology and hepatology.

[24]  Y. Kodera,et al.  TNF-α promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line , 2004, Clinical & Experimental Metastasis.

[25]  Hao Li,et al.  Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. , 2007, World journal of gastroenterology.

[26]  G. Capellá,et al.  Genetic susceptibility and gastric cancer risk , 2002, International journal of cancer.

[27]  T. Hasuma,et al.  Transforming Growth Factor‐β and Hepatocyte Growth Factor Produced by Gastric Fibroblasts Stimulate the Invasiveness of Scirrhous Gastric Cancer Cells , 1997, Japanese journal of cancer research : Gann.

[28]  M. Smyth,et al.  Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.

[29]  I. Beales Effect of Interlukin-1β on proliferation of gastric epithelial cells in culture , 2002, BMC Gastroenterology.

[30]  Tomoyuki Kato,et al.  TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. , 2004, Clinical & experimental metastasis.

[31]  H. Fujii,et al.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  T. Majima,et al.  The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. , 2002, Anticancer research.

[33]  A. Tsamandas,et al.  TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. , 2007, The Journal of surgical research.

[34]  Y. Maehara,et al.  Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Islami,et al.  Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis , 2008, British Journal of Cancer.

[36]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[37]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[38]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[39]  S. Wahl,et al.  TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. , 2003, Cytokine & growth factor reviews.

[40]  S. Fan,et al.  Ischemia‐reperfusion of small liver remnant promotes liver tumor growth and metastases—Activation of cell invasion and migration pathways , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[41]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  C. Abnet,et al.  Interleukin-1B Polymorphisms and Gastric Cancer Risk—A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[43]  Kazumichi Yoshida,et al.  Impact of Postoperative Infection on Long-Term Survival After Potentially Curative Resection for Gastric Cancer , 2009, Annals of Surgical Oncology.

[44]  S. Kanaji,et al.  Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters , 2007, Journal of surgical oncology.

[45]  Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. , 1994, IARC monographs on the evaluation of carcinogenic risks to humans.

[46]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[47]  S. Tatebe,et al.  Serum interleukin-6 and -10 levels in patients with gastric cancer , 2009, Gastric Cancer.

[48]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[49]  H. Tsuda,et al.  Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer , 2008, Journal of surgical oncology.

[50]  Hiroki Takahashi,et al.  Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. , 2008, The Journal of surgical research.

[51]  Megumi Baba,et al.  The role of circulating IL‐8 and VEGF protein in the progression of gastric cancer , 2003, Cancer science.

[52]  T. Ichikura,et al.  Interleukin-1α concentration in tumors as a risk factor for liver metastasis in gastric cancer , 1999, Surgery Today.

[53]  G. Daar,et al.  Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. , 1995, Cancer letters.

[54]  T. Majima,et al.  Interleukin‐10 and interferon‐gamma levels within the peritoneal cavity of patients with gastric cancer , 2001, Journal of surgical oncology.

[55]  S. Tsujitani,et al.  The expression of transforming growth factor‐β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma , 1999, Cancer.

[56]  Masao Tanaka,et al.  Immunosuppressive cytokines (IL‐10, TGF‐β) genes expression in human gastric carcinoma tissues , 1996, Journal of surgical oncology.

[57]  A. Ben-Baruch Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. , 2006, Seminars in cancer biology.

[58]  Carlo Riccardo Rossi,et al.  Tumor necrosis factor, cancer and anticancer therapy. , 2005, Cytokine & growth factor reviews.

[59]  Y. Oshika,et al.  Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  M. Zembala,et al.  Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. , 2009, Anticancer research.

[61]  D. Parkin International variation , 2004, Oncogene.

[62]  Y. Goto,et al.  Genetic factors involved in the development of Helicobacter pylori‐related gastric cancer , 2006, Cancer science.

[63]  D. Cho,et al.  The dual effects of interleukin-18 in tumor progression. , 2007, Cellular & molecular immunology.

[64]  A. Tsamandas,et al.  TGFβ1, TGFβ2, and TGFβ3 Protein Expression in Gastric Carcinomas: Correlation with Prognostics Factors and Patient Survival , 2007 .

[65]  L. Lourenço,et al.  Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. , 2001, Hepato-gastroenterology.

[66]  S. Hwang,et al.  Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.

[67]  T. Majima,et al.  Preoperative serum interleukin‐18 level as a postoperative prognostic marker in patients with gastric carcinoma , 2001, Cancer.

[68]  K. Arihiro,et al.  Tumor-driven evolution of immunosuppressive networks during malignant progression. , 2006, Cancer research.

[69]  S. Paterson-Brown,et al.  Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer , 2006, British Journal of Cancer.

[70]  K. Yanagihara,et al.  Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. , 1992, Cancer research.

[71]  S. Tsujitani,et al.  Interleukin‐10 expression significantly correlates with minor CD8+ T‐cell infiltration and high microvessel density in patients with gastric cancer , 2006, International journal of cancer.

[72]  T. Ichikura,et al.  Interleukin-1alpha concentration in tumors as a risk factor for liver metastasis in gastric cancer. , 1999, Surgery today.

[73]  Y. Liu,et al.  TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. , 2009, Acta biochimica et biophysica Sinica.

[74]  F. Clavel-Chapelon,et al.  Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  H. Okamura,et al.  Endotoxin-induced serum factor that stimulates gamma interferon production , 1989, Infection and immunity.

[76]  H. Fujii,et al.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.

[77]  S. Todo,et al.  Surgical stress and tumor behavior: Impact of ischemia‐reperfusion and hepatic resection on tumor progression , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[78]  Min Yan,et al.  Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients , 2007, Journal of Zhejiang University SCIENCE B.

[79]  H. Fujii,et al.  Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. , 2005, The Journal of surgical research.

[80]  J. Hadden Immunodeficiency and cancer: prospects for correction. , 2003, International immunopharmacology.

[81]  M. Braga,et al.  Increased interleukin-10 serum levels in patients with solid tumours. , 1996, Cancer letters.

[82]  H. Yokozaki,et al.  Expression of Interleukin‐6 and Its Effect on the Cell Growth of Gastric Carcinoma Cell Lines , 1997, Japanese journal of cancer research : Gann.

[83]  C. V. van Duijn,et al.  A Systematic Review of Meta-Analyses on Gene Polymorphisms and Gastric Cancer Risk , 2008, Current genomics.

[84]  N. Shinomiya,et al.  Relationship between interleukin-1-alpha concentration in tumors and cell growth in gastric cancer, determined using flow cytometry , 2000, Gastric Cancer.

[85]  Shiu-Feng Huang,et al.  Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways , 2003, Oncogene.

[86]  M. Fukuzawa,et al.  Decreased Production of Interleukin-12 and Type 2 Immune Responses Are Marked in Cachectic Patients with Colorectal and Gastric Cancer , 2002, Journal of clinical gastroenterology.

[87]  G. Catalano,et al.  Serum interleukin‐10 levels in patients with advanced gastrointestinal malignancies , 1999, Cancer.

[88]  Victor M Montori,et al.  Conducting systematic reviews of diagnostic studies: didactic guidelines , 2002, BMC medical research methodology.

[89]  M. Kinoshita,et al.  Exploitation of interleukin‐18 by gastric cancers for their growth and evasion of host immunity , 2006, International journal of cancer.

[90]  M. Kinoshita,et al.  Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination , 2008, International journal of cancer.

[91]  T. Jang The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. , 2010, Pathology, research and practice.